Other

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents

Alnylam Pharmaceuticals Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents increased by 1492.0% to $1.40M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2025
Last reportedQ1 2026
Metric ID: other_debt_securities_available_for_sale_accumulated_gro_86a77e

Historical Data

2 periods
 Q4 '25Q1 '26
Value$88.00K$1.40M
QoQ Change—>999%
Range$88.00K – $1.40M

Frequently Asked Questions

What is Alnylam Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax, including cash equivalents?
Alnylam Pharmaceuticals (ALNY) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax, including cash equivalents of $1.40M in Q1 2026.